Skip to content

Work in process at other companies

10x Genomics, Inc. logo
10x Genomics, Inc.TXG
$18.83M-19.0%
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Danaher logo
DanaherDHR
Revvity logo
RevvityRVTY
Bruker logo
BrukerBRKR

Other financials

Income statement

See full
Revenue$44.1M+6.5%
Gross profit$21.3M+5.4%
Operating income-$18.5M-23.3%
Net income-$18.9M-65.5%
EPS (diluted)-$0.15-66.7%

Balance sheet

See full
Cash & equivalents$31.8M-66.6%
Total debt$16.8M+40.9%
Total equity$327.6M-13.7%
Total assets$449.1M-6.9%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+155%
Free cash flow-$4.9M-403%

Valuation

See full
Market cap$577.27M+54.5%
Enterprise value$562.23M+93.7%
P/S2.8×+0.9×

Profitability

See full
Gross margin51.7%-3.2pp
Operating margin-21.5%
Net margin-36.2%
FCF margin-6.2%-15.1pp

Returns & leverage

See full
Return on equity-20.9%
Debt / equity0.1×0.0×
Current ratio4.7×-0.9×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InventoryWorkInProcess.

The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytek Biosciences, Inc.'s work in process.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytek Biosciences, Inc.'s work in process?
Cytek Biosciences, Inc. (CTKB) reported work in process of $16.34M in Q1 2026.
What does work in process mean?
Partially completed goods currently in the manufacturing process, including materials, labor, and overhead costs incurred to date.